4-phenylbutyric acid promotes hepatocellular carcinoma via initiating cancer stem cells through activation of PPAR-α

Shu-Zhen Chen1,2,‡ | Yan Ling1,2,‡ | Le-Xing Yu1,2,‡ | Yu-Ting Song1,2,3,‡ |
Xiao-Fei Chen4 | Qi-Qi Cao1,2 | Han Yu1,2 | Can Chen1,2,6 | Jiao-Jiao Tang1,7 |
Zhe-Cai Fan1 | Yu-Shan Miao1,2, | Ya-Ping Dong1,2,6 | Jun-Yan Tao8 |
Satdarshan P.S. Monga8,9 | Wen Wen1,2 | Hong-Yang Wang1,2,3,5,6,7,‡

1 National Center for Liver Cancer, Second Military Medical University, Shanghai, China
2 International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China
3 Model Animal Research Center, Nanjing University, Nanjing, Jiangsu Province, China
4 School of Pharmacy, Second Military Medical University, Shanghai, China
5 State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
6 Fujian Medical University, Fuzhou, Fujian Province, China
7 Cancer Research Center, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui Province, China
8 Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
9 Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Correspondence
Hong-Yang Wang, International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Hospital, 225 Changhai Road, Shanghai 200438, China.
Email: hywangk@vip.sina.com
Wen Wen, International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Hospital, 225 Changhai Road, Shanghai 200438, China.
Email: wenwen_smmu@163.com

Graphical Abstract

1. 4-PBA could promote HCC at early stage of tumor development in vivo.
2. 4-PBA initiated CSCs via activating Wnt5b-Fzd5-β-catenin signaling pathway dependent of PPAR-α activation.
3. 4-PBA could not only regulate the expression of PPAR-α transcriptionally, but also stabilize it via direct binding.
4-phenylbutyric acid promotes hepatocellular carcinoma via initiating cancer stem cells through activation of PPAR-α

Shu-Zhen Chen1,2,‡ | Yan Ling1,2,‡ | Le-Xing Yu1,2,‡ | Yu-Ting Song1,2,3,‡ | Xiao-Fei Chen4 | Qi-Qi Cao1,2 | Han Yu1,2 | Can Chen1,2,6 | Jiao-Jiao Tang1,7 | Zhe-Cai Fan1 | Yu-Shan Miao1,2 | Ya-Ping Dong1,2,6 | Jun-Yan Tao8 | Satdarshan P.S. Monga8,9 | Wen Wen1,2 | Hong-Yang Wang1,2,3,5,6,7,‡

1 National Center for Liver Cancer, Second Military Medical University, Shanghai, China
2 International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China
3 Model Animal Research Center, Nanjing University, Nanjing, Jiangsu Province, China
4 School of Pharmacy, Second Military Medical University, Shanghai, China
5 State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
6 Fujian Medical University, Fuzhou, Fujian Province, China
7 Cancer Research Center, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui Province, China
8 Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
9 Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Correspondence
Hong-Yang Wang, International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Hospital, 225 Changhai Road, Shanghai 200438, China.
Email: hywangk@vip.sina.com
Wen Wen, International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Hospital, 225 Changhai Road, Shanghai 200438, China.
Email: wenwen_smmu@163.com

‡These authors contributed equally to this work.

Funding information
National Natural Science Foundation of China, Grant/Award Numbers: 81802878, 81722034, 81572896, 81773077, 82002522, 81830054, 91859205, 8198101; Shanghai Sailing Program, Grant/Award Number: 18YF1400200; Shanghai Pujiang Program, Grant/Award Number: 18Pb0410400.

Abstract
Background and aims: 4-phenylbutyric acid (4-PBA) is a low molecular weight fatty acid that is used in clinical practice to treat inherited urea cycle disorders. In previous reports, it acted as a chemical chaperone inhibiting endoplasmic reticulum (ER) stress and unfolded protein response signaling. A few studies have suggested its function against hepatic fibrosis in mice models. However, its role in hepatocarcinogenesis remained unknown.

Methods: 4-PBA was administered alone or in combination with diethylnitrosamine to investigate its long-term effect on liver tumorigenesis. The role of 4-PBA in oncogene-induced hepatocellular carcinoma (HCC) mice model using sleeping beauty system co-expressed with hMet and β-catenin point mutation (S45Y) was also observed. RNA-seq and PCR array were used to screen the pathways and genes involved. In vitro and in vivo studies were conducted to explore the effect of 4-PBA on liver and validate the underlying mechanism.

Results: 4-PBA alone didn’t cause liver tumor in long term. However, it promoted liver tumorigenesis in HCC mice models via initiation of liver cancer stem cells (LCSCs) through Wnt5b-Fzd5 mediating β-catenin signaling. Peroxisome...
proliferator-activated receptors (PPAR)-α induced by 4-PBA was responsible for the activation of β-catenin signaling. Thus, intervention of PPAR-α reversed 4-PBA-induced initiation of LCSCs and HCC development in vivo. Further study revealed that 4-PBA could not only upregulate the expression of PPAR-α transcriptionally but also enhance its stabilization via protecting it from proteolysis. Moreover, high PPAR-α expression predicted poor prognosis in HCC patients.

Conclusions: 4-PBA could upregulate PPAR-α to initiate LCSCs by activating β-catenin signaling pathway, promoting HCC at early stage. Therefore, more discretion should be taken to monitor the potential tumor-promoting effect of 4-PBA under HCC-inducing environment.

KEYWORDS
4-phenylbutyric acid (4-PBA), cancer stem cell (CSC), hepatocellular carcinoma (HCC), peroxisome proliferator-activated receptor-α (PPAR-α)

1 INTRODUCTION

Liver cancer is a common solid tumor worldwide with nearly 800,000 new cases annually and ranks as the third leading cause of cancer-related deaths. Hepatocellular carcinoma (HCC) alone accounts for 90% of all primary liver cancer cases with poor prognosis. Identification of chemical compounds that pose great threat to HCC is an effective approach for HCC prevention. During the past years, various risk factors of HCC were identified, including ingestion of the fungal metabolite Aflatoxin B1, hepatitis B virus infection, hepatitis C virus infection, nonalcoholic fatty liver disease (NAFLD), and alcohol intake. Hepatocytes injury caused by these risk factors initiated the damage repair mechanism and created a chronic inflammatory environment which facilitated the initiation of liver cancer stem cells (LCSCs) and the subsequent budding of liver cancer.

4-phenylbutyric acid (4-PBA) is a small molecular weight fatty acid approved by the Food and Drug Administration (FDA) as a well-tolerated drug for patients with urea cycle disorders and hyperammonemia (450 mg/kg/day in patients weighing less than 20 kg, or 9.9–13.0 g/m²/day in larger patients), where it plays the role of an ammonia scavenger. It has been regarded as a novel chemical chaperone to reduce endoplasmic reticulum (ER) stress due to its role in stabilizing protein conformation, improving ER folding capacity, and facilitating the trafficking of proteins. With the recognition of ER stress dysregulation caused human diseases, the role of 4-PBA in obesity, diabetes, ischemic injury, and liver fibrosis etc. has been explored, providing novel drug targets and promising strategies for therapeutic intervention. 4-PBA was identified as a suppressor of tumor cell growth decade ago. However, a recent study has found that 4-PBA promoted gastric cancer cell migration via mediating HER3/HER4 upregulation. Since 4-PBA is derived from butyric acid, which is produced in the digestive tract by colonic bacteria, it could be involved in liver diseases where gut-derived nutrients and microbiota-derived signals constantly flood via the portal system. Several studies have indicated a protective role of 4-PBA in liver injury. Data showed that 4-PBA prevented CCl₄-induced hepatic fibrosis via impeding hepatic inflammatory response and hepatic stellate cells activation. It could attenuate ER stress-mediated apoptosis and protect hepatocytes from intermittent hypoxia-induced injury. Meanwhile, it was also responsible for reducing hepatocellular lipid accumulation and lipotoxicity through induction of autophagy. However, the above studies only focused on short-term effect of 4-PBA on liver injury. The long-term effect of 4-PBA on liver tumorigenesis remained unknown.

In this study, we evaluated the role of 4-PBA in HCC carcinogenesis. Our data showed that 4-PBA significantly increased liver tumor burden in diethylinitrosamine (DEN) or 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) supplemented HCC models when administered at an early stage, even though liver inflammation and fibrosis seemed alleviated. 4-PBA functioned via initiation of LCSCs by activating Wnt5b-Fzd5 mediating β-catenin pathway in a peroxisome proliferator-activated receptors (PPAR)-α dependent manner. Further study revealed that 4-PBA not only upregulated the expression of PPAR-α, but also stabilized it via directly binding to it. Moreover, intervention of PPAR-α with inhibitor or short hairpin RNA (shRNA) reversed the tumor-promoting effect of 4-PBA. Meanwhile,
high PPAR-α expression predicted poor prognosis in HCC patients. Our study suggested that 4-PBA could cause liver tumorigenesis in HCC-inducing environment via initiating LCSCs. Therefore, more caution should be taken for long-term use of 4-PBA in clinical practice.

2 | MATERIALS AND METHODS

2.1 | Experimental animal models

Male C57BL/6 and nude mice were purchased from Shanghai Experimental Center of Chinese Academy of Science and maintained under pathogen-free conditions. Each group includes more than six mice except otherwise indicated. The HCC model in mice was induced by injection of DEN (Sigma-Aldrich, St. Louis, MO, 25 mg/kg) intraperitoneally at age of 15 days. A single injection of DEN was followed by administration of carbon tetrachloride (CCl4) 1 ml/kg per week. Mice were fed without or with 1 g/kg/day of 4-PBA supplemented in the drinking water. Randomly grouped mice were infected with adeno-associated virus (AAV)-shNC (3 × 1011 IU/animal; i.p., n = 5) or AAV-shPpara (3 × 1011 IU/animal; i.p., n = 6). AAV was constructed and purchased from Obio technology company (Shanghai, China).

For hMetS45Y-β-catenin and hMet model, hydrodynamic tail vein injections were performed. Briefly, 20 mg pT3-EF5a-hMet-V5 or pT3-EF5a S45Y-β-catenin-Myc or the combination of pT3-EF5a-hMet-V5 and pT3-EF5a-S45Y-β-catenin-Myc, accompanied with the sleeping beauty (SB) transposase were diluted in 2 ml of normal saline (0.9% NaCl) in a ratio of 25:1 and injected into the tail vein of 6 to 8-week-old C57BL/6 mice in 5–7 seconds.

All animals received humane care according to the criteria outlined in the “Guide for the Care and Use of Laboratory Animals,” and the animal experiments protocols were approved by the Institutional Animal Care and Use Committee of Second Military Medical University.

2.2 | Drug affinity responsive target stability assay

Studies were performed as previously reported.29 Cells were lysed and treated with various concentrations of 4-PBA followed by digestion with pronase and stopped by SDS-PAGE loading buffer. Samples were run on a SDS-PAGE electrophoresis gel for silver staining. 4-PBA-protected candidate proteins were identified and confirmed by western blotting. The details are described in supplementary materials.

2.3 | Statistical analysis

All data are presented as means with the standard deviation unless otherwise indicated. For comparisons of two groups, two-tailed unpaired Student’s t-test was performed. Cumulative survival time was calculated with the Kaplan-Meier method and analyzed by the log-rank test. Univariate and multivariate analyses were based on the Cox proportional hazards regression model. A p-value < 0.05 was considered statistically significant. Statistical calculations were performed using SPSS 16.0 software (SPSS, Chicago, IL, USA).

3 | RESULTS

3.1 | 4-PBA promoted chemical carcinogen-induced and driver gene-induced HCC carcinogenesis in vivo

To test the effect of 4-PBA on HCC development in vivo, male C57BL/6 mice were fed with a normal diet for 4 months supplemented with or without 4-PBA (1.0 g/kg/day) in the drinking water. No liver tumor was observed with 4-PBA treatment alone after 40 weeks (Figure S1A), indicating that 4-PBA was incapable of initiating HCC. We further used chemical-induced HCC model via a single injection of DEN followed by repeated administration of carbon tetrachloride (CCl4). A dramatic potentiation of liver tumor incidence indicated by more and larger tumors was observed in 4-PBA supplemented mice when evaluated at the time point of 16 and 20 weeks (Figures 1A, S1B and S1C). Hepatic nuclear factor 4 alpha (Hnf-4α), a marker of differentiated hepatocyte, was down-regulated in 4-PBA treated liver, whereas more ductular reaction marked by CK19 and enhanced cell proliferation marked by Ki-67 were observed at 16 weeks (Figure 1B).

As liver carcinogenesis induced by DEN alone in mice closely mimics the pathology during human liver cancer initiation and progression, we observed the effect of 4-PBA in a single dose DEN treated mouse model. Consistent with the previous model, tumor incidence was also enhanced in 4-PBA supplemented mice, suggested by enlarged liver/body weight ratio, tumor number, and tumor size (Figure 1C). DDC could induce severe cholestatic liver injury with strong ductular reaction; however, DDC alone rarely initiated liver tumorigenesis. When mice fed with DDC diet were sacrificed after 57 weeks, 4-PBA treated mice have developed visible liver tumors, while no tumor was observed in the control group (Figure S1D). The above models demonstrated that 4-PBA promoted chemical carcinogen-induced HCC.
We next introduced concomitantly expressed hMet and an S45 to tyrosine (Y) mutant form of β-catenin (S45Y-β-catenin, with a Myc tag) using SB transposon/transposase (henceforth referred to as hMetS45Y-β-catenin model) to C57BL/6 mice via hydrodynamic tail vein injection to model human HCC in mice as previously described. In this model, clusters of small microscopic foci with basophilic hepatocytes could be detected as early as 4 weeks after 4-PBA treatment (Figure 1D). Myc-tag could be detected in both groups at this time (Figure S1E). Notable tumor burden with areas of necrosis could be observed in 4-PBA treated group 8 weeks after plasmids injection, demonstrated by larger macroscopic tumors and liver/body weight ratio (Figure 1E). The above data indicated that 4-PBA could also accelerate tumorigenesis in short-term HCC model. Taken together, 4-PBA promotes liver tumor development both in long-term chemical carcinogen-induced HCC models and short-term driver gene-induced model.

3.2 4-PBA gave rise of HCC at early stage of tumor development

To define the time frame when 4-PBA affected liver tumor development, we altered the time of 4-PBA administration in DEN-induced HCC model (Figures 2A and 2D). Liver tumorigenesis was markedly increased when 4-PBA was supplemented 2 weeks after DEN injection (early stage of tumor development), even though it was withdrawn 8 weeks later (Figure 2A). In 4-PBA group, macroscopic tumors occurred at as early as the 10th week, and abundant tumors could be observed at 16th week (Figure 2B). Moreover, liver/body weight ratio, tumor number, and tumor size were significantly increased compared with control group (Figure 2C). However, when 4-PBA was supplemented at later stage after DEN injection for 10 weeks (later stage of tumor development), liver tumorigenesis in 4-PBA combined group was not significantly affected, suggested by comparable tumor number and maximum tumor size with control group (Figures 2D-2F). These two models suggested a synergic effect of 4-PBA with DEN in early stage of liver cancer formation.

3.3 4-PBA promoted tumorigenesis via initiation of cancer stem cells instead of inflammation and ER stress-dependent way

We tested the effect of 4-PBA in vitro and found that 4-PBA does not significantly accelerate the proliferation of hepatocyte cell line L02 and HCC cell line HepG2 (Figures S2A and S2B). Established data showed that the inflammatory microenvironment played an important role in liver cancer initiation. Previous study has revealed a protective role of 4-PBA in hepatic fibrosis via inhibiting hepatic inflammatory responses. In our study, liver fibrosis caused by CCl4 was ameliorated by 4-PBA administration measured by Sirius red and α-SMA expression detection (Figures S2C and S2D). IHC staining of F4/80 revealed rare increase of Kupffer cells in the liver of 4-PBA supplemented mice (Figure S2E). Meanwhile, similar levels of TNF-α were presented in both groups (Figure S2F). In 4-PBA alone treated mice, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) level were not significantly altered (Figure S2G). Whereas, they were significantly lower in 4-PBA supplemented mice in DEN plus CCl4 model (Figure S2H), suggesting a possibly relieved inflammation environment. Next, we determined the role of 4-PBA on ER stress and apoptosis in the above model. 4-PBA reduced p-PERK at 2 weeks after treatment, but it was restored 4 weeks later (Figure S2I). TUNEL assay revealed that DEN-induced apoptosis was significantly reduced in the liver of 4-PBA supplemented mice (Figure S2I). However, the expression of CHOP, a downstream molecule of unfolded protein response triggering apoptosis, was not inhibited by 4-PBA (Figure S2I). These data indicated that 4-PBA promoted liver tumorigenesis via mechanism other than inflammation and ER stress-dependent pathways.

Cells with stem-cell properties are involved in HCC initiation. In human, hepatic stem/progenitor cells are markedly elevated in chronic liver diseases. Impairment in hepatocyte proliferation may cause the expansion of stem/progenitor cells called “ductular reactions.” In DEN-induced HCC model, higher expansion of CK19 and SOX9 positive cells was detected as early as 2 weeks after 4-PBA treatment (Figure S3A). Meanwhile, relative mRNA
4-PBA gave rise of HCC at early stage of tumor development. (A) Schematic experimental outline of 4-PBA administration at early stage of tumor development. (B) Representative images of livers at 10 weeks, 16 weeks, and 20 weeks as indicated in 2A. Scale bar: 1 cm. (C) Liver/body weight ratio, tumor number, and tumor size were measured in PBA-treated group and the control group at 16th week. *p < 0.05, **p < 0.01. (D) Schematic experimental outline of 4-PBA administration at later stage of tumor development. (E) Representative images of livers at 20 weeks as indicated in 2D. Scale bar: 1 cm. (F) Tumor number and maximum diameter of tumors in 2E were measured in PBA-treated group and the control group.

of α-Fetoprotein (Afp) and long noncoding RNA-H19 (H19), both imprinted oncogenic gene, were significantly upregulated in the liver of 4-PBA treated group (Figure S3B). Higher CD133 expression was detected in fresh frozen sections from the liver of 4-PBA supplemented mice for 6 weeks (Figure 3A), along with the elevation of other CSC-related genes, including Epcam, Cd90, Bmi-1, Oct-4, Sox-2, Cd133, and Stat3 (Figure 3B). In DDC-diet model, stronger ductular reaction indicated by SOX9 and CK19 staining could also be observed at 4 weeks in 4-PBA supplemented mice (Figure S3C), with elevated expression of EpCAM in liver sections (Figure S3D). These data suggested the
FIGURE 3 4-PBA promoted tumorigenesis via initiation of cancer stem cells. (A) Representative photos of CD133 immunofluorescence of the fresh liver section in DEN plus CCl₄ HCC model after 6 weeks with or without PBA. Scale bar: 25 μm. (B) Relative expression of Epcam, Cd90, Bmi1, Oct-4, Sox2, Cd133, and Stat3 in DEN plus CCl₄ mice liver after 6 weeks. *p < 0.05. (C) Relative expression of Cd90, Cd133, Epcam, Lgr5, Sox2, Sox9, and Nanog in hMetS45Y-β-catenin model after 8 weeks. *p < 0.05, **p < 0.01. (D) Representative pictures of tumors in nude
activation of LCSCs under the effect of 4-PBA in chemical-induced HCC model. In hMetS45Y-β-catenin model, six of seven CSC markers were upregulated in 4-PBA-treated mouse liver after 4 weeks (Figure 3C). More Cd133 and Epcam positive cells could be observed in these liver tissues (Figures S3E and S3F). In nude mice xenograft model, HCC cell line Huh7 was injected subcutaneously, and 4-PBA was supplemented in drinking water the day after. As expected, 4-PBA played tumor-promoting role with more and larger tumors formed than the control group (Figures 3D and S3G). Meanwhile, a subset of stem-cell-related genes such as Cd90 and Cd133 were significantly upregulated in tumor tissues of 4-PBA-treated group (Figure 3D). Furthermore, limiting dilution assay was performed with HepG2, which also exhibited enhanced tumor initiating capacity with 4-PBA treatment (Figure S3H).

We also demonstrated the role of 4-PBA on CSCs in vitro. Flow cytometry analysis detected an increase of CD133 and CD24 positive cells in Huh7 cell line cultured with 4-PBA (Figure 3E). In sphere formation assay, more spheres were formed when 4-PBA was supplemented in culture medium (Figure 3F). Similarly, 4-PBA induced more colonies of HepG2 in soft agar (Figure S3I). Therefore, we concluded that 4-PBA played a tumor-promoting role in liver via initiating LCSCs other than inflammation and ER stress-dependent way.

### 3.4 4-PBA regulated CSCs via Wnt5b-Fzd5 mediating β-catenin signaling pathway

Various pathways are reported to be involved in CSC initiation in tumors. To identify functional pathways involved, we conducted PCR array to screen mouse stem cell relevant signaling in livers treated with or without 4-PBA for 6 weeks in DEN plus CCl⁴ model, including 90 genes such as Fzd1-9, Smad1-9 etc. Our result suggested that nine genes were significantly overexpressed in 4-PBA treated livers (Figure 4A). Among them, Fzd5, a mediator in non-canonical β-catenin pathway, was the most notably upregulated gene with a fold change of 8.66, indicating that Wnt-β-catenin signaling might be responsible for 4-PBA-induced CSC initiation (Figure 4A). The activation of Fzd5 was further confirmed by RT-PCR and western blot (Figures 4B and 4C).

Next, we investigated the molecules involved in activating this pathway. As histone H3 trimethylated at lysine 4 (H3K4me3) is associated with active chromatin and gene expression, we used H3K4me3 antibody as the binding protein in chromatin immunoprecipitation sequencing (CHIP-seq) to detect possible active gene transcription in primary hepatocyte separated from the above model. The result showed 366 peaks of 289 varied genes. Of the 366 peaks, 43 were upregulated, and 323 were downregulated (Data not shown). Gene distribution heatmap and KEGG pathway classification of the differential genes are presented (Figures 4D and 4E). We next screened 159 Wnt signaling-related genes among 289 varied genes with peaks, of which Wnt5b was detected as the only overlapped gene (Figures 4F and 4G), indicating that Wnt5b might be the target gene of 4-PBA. Wnt5b is a paralog of Wnt5a, serves as the ligand for Fzd5, which could be secreted to instigate the invasion of epithelial cancer cells. Interestingly, in serial liver sections of DEN model, we could detect elevated level of Wnt5b, Fzd5, and β-catenin located along the ductular area, especially in 4-PBA supplemented mice (Figure 4H), demonstrating that Wnt5b-Fzd5-β-catenin pathway was activated by 4-PBA.

We further confirmed the regulation of Wnt5b by 4-PBA in vitro. MHCC-LM3 was cultured in serum-free medium supplemented with different doses of 4-PBA (0, 1, 5, 10 mM) for 24 h. The mRNA level of Wnt5b elevated with the increased concentration of 4-PBA (Figure 4I). Moreover, 4-PBA could induce a dose-dependent increase of secreted Wnt5b in supernatant and intracellular Wnt5b in cell lysate as detected by ELISA (Figure 4I). We also confirmed the result in Huh7 cell line under the same culture condition (Figure 4J). To further validate if Wnt5b-β-catenin pathway is responsible for 4-PBA promoted LCSCs initiation and HCC development, XAV939, an inhibitor to block the activation of β-catenin signaling was utilized. Huh7 was cultured in medium with 4-PBA and different doses of XAV939 (0, 5, 10 μM) for 7 days. It turned out that XAV939 notably shrunk the number of spheres formed, indicating weakened stemness (Figure 4K). XAV939 also alleviated tumor burdens in Huh7 xenograft model at the presence of 4-PBA (Figure 4L). Therefore, 4-PBA could induce the expression of wnt5b and subsequently activate β-catenin pathway.

In previous hMetS45Y-β-catenin model, enhanced hMet expression and β-catenin activation could successfully
FIGURE 4 4-PBA regulated CSCs via activating Wnt5b-Fzd5 mediating β-catenin signaling pathway. (A) Heatmap of mouse stem cell signaling-related genes determined by PCR array. Each group includes three samples. The arrow points at the expression of Fzd5, which is significantly increased in 4-PBA treated group. The table represented top five overexpressed stem cell-related genes in liver samples of
model HCC. However, mice injected with hMet or β-catenin mutant alone did not show any morbidity even after 22 weeks.\(^3\) To further investigate whether 4-PBA exerts its function via activating β-catenin pathway, we replaced S45Y-β-catenin with 4-PBA (only pT3-EF5a-hMet-V5 and pCMV/SB transposase are injected, referred to as hMet model) to see if it could mimic the tumorigenesis effect of hMetS45Y-β-catenin model. In hMet model, no tumors could be observed in control group or 4-PBA-treated group after 8 weeks. However, when the observation was prolonged to 14 weeks, multiple tumor nodules occurred in 4-PBA treated group (Figure 4M), while no tumor was observed in control group. Liver/body ratio in 4-PBA-treated group was about twice that of the control group (Figure 4M). Histology of 4-PBA-treated liver at 14 weeks was comparable to hMetS45Y-β-catenin model at 8 week (Figure 4N), which suggested that 4-PBA could replace S45Y-β-catenin to cause liver tumorigenesis. The distribution of EpCAM positive liver cells was similar to hMetS45Y-β-catenin model (Figure 4O), which showed an intensive accumulation of Wnt5b, Fzd5, and β-catenin in liver samples of 4-PBA-treated group (Figure 4P). Taken together, we concluded that 4-PBA activated Wnt5b-Fzd5-β-catenin signaling, leading to CSCs initiation.

### 3.5 PPAR-α signaling was involved in 4-PBA induced tumorigenesis

To disclose the molecular mechanism underling 4-PBA-induced cancer stem cell initiation, liver samples in DEN plus CCl\(_4\) model were analyzed at the transcription level by RNA-seq. The expression of 1,893 genes was altered under 4-PBA treatment for 6 weeks. The pathways most highly enriched included the olfactory transduction, PPAR signaling pathway and retinol metabolism (Figure 5A). Thirty-seven genes were differentially expressed in PPARs signaling pathway (Figure 5B), which was reported to be involved in tumorigenesis among various tissues.\(^3\) PPARs are ligand-activated transcription factors of nuclear hormone receptor superfamily, comprising of PPAR-α, PPAR-γ, and PPAR-β/δ. Among them, expression of PPAR-α was specifically upregulated by 4-PBA (Figure 5C), which was further validated by western blot (Figure 5D). To further verify the activation of PPAR-α, we confirmed the expression of its downstream target genes in liver samples. RT-PCR revealed an increased level of enzymes involved in fatty acid β-oxidation such as *Ehhadh* and *Acocl* in 4-PBA-treated group (Figure 5E). Furthermore, in hMetS45Y-β-catenin model, the expression of PPAR-α in 4-PBA treated group was also elevated at the indicated time points, even when tumors were already formed at the 8th week (Figure 5F).

Next, we evaluated the effect of 4-PBA on the expression of PPAR-α in vitro. Cultured hepatocyte (L02) and HCC cell line MHCC-LM3 were treated with 4-PBA or vehicle. RT-PCR revealed that 4-PBA induced an increase of PPAR-α and its related genes in a time and dose-dependent manner (Figures 5G-5I). Notably, low concentration of 4-PBA was able to induce significant accumulation of PPAR-α (Figure 5H).

We further validated the activation of PPAR-α and its role in tumorigenesis by using GW7647, a highly potent PPAR-α selective agonist, to replace 4-PBA in DEN induced HCC model. It turned out that GW7647 could simulate similar effect of 4-PBA (Figure 5J), with more and larger tumor formed in livers and enhanced liver/body ratio (Figure 5K). We next explored whether PPAR-α...
Figure 5  PPAR-α signaling was involved in 4-PBA induced tumorigenesis. (A) KEGG pathways were enriched in liver samples of DEN plus CCl₄ model after 6 weeks with or without PBA treatment. The arrow points at PPAR signaling pathway. (B) Liver samples in DEN plus CCl₄-induced HCC mice model were analyzed at the transcriptional level by RNA-seq. Thirty-seven genes are differentially expressed in
inhibition could reverse the tumor promoting effect of 4-PBA. GW6471, a PPAR-α antagonist was used to inhibit PPAR-α activation in Huh7 xenograft model. With the administration of GW6471 for 2 weeks, the tumor promoting effect of 4-PBA was notably impaired (Figure 5L). Analysis of the tumors suggested that GW6471 impeded CSCs expansion as indicated by lowered level of CSCs markers (Figure 5M). Furthermore, we have constructed AAV expressing shRNA targeting PPAR-α (Figure 5N). Western blot confirmed that PPAR-α could be downregulated in vivo by AAV-delivered shRNA (Figure 5O). As expected, a single injection of AAV-shPpara 2 weeks after DEN injection could ameliorate 4-PBA enhanced tumorigenesis in liver, with significantly reduced tumor burden after 14 weeks (Figure 5P). The expression of CSCs-related genes after AAV-shPpara injection for 6 weeks in 4-PBA group was significantly decreased (Figure 5Q). Besides, ductular reaction marked by Sox9 and CK19 was notably ameliorated both in 4-PBA-treated group of DDC-diet and DEN-induced HCC model when the expression of PPAR-α was interfered (Figures S4A and S4B).

Our data also showed that PPAR-α was associated with cancer stem cell initiation in vitro. GW6471 treatment reversed the increase of CD133 positive cells induced by 4-PBA (Figure S4C). Meanwhile, sphere formation ability induced by 4-PBA was impaired with GW6471, while enhanced by PPAR-α agonist GW7647 (Figures S4D and S4E). Therefore, these data demonstrated that PPAR-α was responsible for 4-PBA induced CSCs initiation and tumorigenesis.

3.6 | PPAR-α was associated with Wnt5b-Fzd5-β-catenin signaling

The above evidence has already proved that Wnt5b-Fzd5-β-catenin signaling and PPAR-α overexpression are related to 4-PBA induced CSCs initiation. Next, we explored whether these two pathways are correlated. Firstly, PPAR-α was knocked down in MHCC-LM3 cell line with Lenti-virus system (negative control: LM3-shNC and LM3-shPPARA). Knockdown of PPAR-α disabled 4-PBA-induced transcription of CSC-related genes compared with its counterpart (Figure 6A). Next, we examined the expression of PPARA, WNT5B, FZD5, and CTNNBI in these cell lines with 4-PBA in culture medium for 24 h. 4-PBA has led to significantly increased transcription of PPARA and WNT5B in LM3-shNC, as we have demonstrated previously. However, the effect of 4-PBA was not as comparable in LM3-shPPARA as its counterpart (Figure 6B). Then, these two cell lines were injected subcutaneous in nude mice to construct xenograft model with 4-PBA supplemented in drinking water. Mice were sacrificed 4 weeks later. Tumors formed in LM3-shPPARA injected group were less and smaller than control group (Figure 6C). With the interference of PPARA, mRNA levels of WNT5B, FZD5, and CTNNBI were respectively lowered, especially WNT5B (Figure 6D). Moreover, PPARA expression is positively correlated with the expression of WNT5B, FZD5, and CTNNBI relatively (Figure 6E). We also verified that WNT5B expression was also correlated with CTNNBI (Figure 6E). These results were further confirmed in Huh7-shNC and Huh7-shPPARA cell lines, which exhibited a similar gene expression pattern and correlation between PPARA and WNT5B, FZD5, or CTNNBI, respectively (Figures 6F and 6G).

We further examined the activation of Wnt5b-Fzd5-β-catenin pathway in liver section of DEN model. By using multiplexed immunohistochemistry to mark different proteins in one section, the images have shown more intensive staining of PPAR-α, β-catenin, and CK19 in 4-PBA-treated group (Figure 6H). In DEN model with AAV-shPpara injection, decreased Wnt5b, Fzd5, and β-catenin positive cells were detected in both control and 4-PBA-treated group in serial sections of liver samples (Figure 6I).
3.7 4-PBA directly bind to PPAR-α and enhanced its stabilization

Our data revealed that 4-PBA could induce significant accumulation of PPAR-α at low concentration in vitro and in vivo, thus we investigated the underlying mechanism. Drug affinity responsive target stability (DARTS) assay was performed as a means to validate binding of compounds to proteins of interest, by detecting the increase in resistance to proteolysis upon the binding of a molecule. Therefore, we used DARTS to explore the protection of PPAR-α by interaction with 4-PBA against proteolysis. Silver-staining showed a strong band at ~55 kDa in the proteolysed extracts of 4-PBA-treated cells (Figure 7A), which was further verified by western blot with PPAR-α specific antibody (Figure 7B). The result was also confirmed by surface plasmon resonance analysis. As shown in Figure 7C, 4-PBA could bind to the recombinant PPAR-α protein in a concentration-dependent manner with a dissociation constant (K_D) value of 12.25 μM. 4-PBA was docked into the active site of PPAR-α crystal model (PDB code: 1K7L) (data not shown). In the computer simulation model presented in Figure 7D, the carboxyl groups form a hydrogen bond with MET220, ASN219, and GLU286 by hydrogen bonding as a donor. The phenyl ring extends into the functional region in α-helix. The binding affinity was predicted to be around −4.27 kcal/mol, suggesting a modest binding potency. Therefore, 4-PBA could not only regulate PPAR-α transcriptionally, but also directly bind to it and enhance its stability.

3.8 PPAR-α expression correlates with the prognosis of HCC patients

PPAR-α expression of 263 HCC patient samples was evaluated by IHC staining and divided into two groups according to the median of staining intensity. Patients with higher level of PPAR-α expression (n = 131) exhibited significantly increased recurrence rate and shorter overall survival (OS) compared to those with lower expression of PPAR-α expression (n = 132) (Figure 8A). Clinical pathological characteristics of HCC patients were presented in Table S1. Univariate and multivariate analysis also revealed that PPAR-α expression was an independent prognostic factor for recurrence and OS, besides tumor diameter and tumor number etc. (Figures 8B and 8C).

In conclusion, 4-PBA is responsible for the accumulation of PPAR-α both in mRNA level and protein level, activating Wnt5b-β-catenin pathway and initiating LCSCs, which subsequently promotes liver tumorigenesis under HCC-inducing environment (Figure 8D).

4 DISCUSSION

4-PBA, a pharmacologically available derivative of butyrate, can act at almost the same way as the unmodified BA, which is reported to have a beneficial role in prevention of malignancies. The addition of phenyl group has enriched 4-PBA with chaperon-like properties, concerning with restoration of tissue homeostasis in multiple researches. According to the success of preclinical studies, PBA has been approved by the U.S. FDA for clinical use...
FIGURE 7 4-PBA directly binded to PPAR-α and enhanced its stabilization. (A) Silver-staining showed a strong band at ~55 kDa (as the arrow indicated) in the proteolysed extracts of 4-PBA-treated cells, independent of 4-PBA concentration (0.5 mM, 1.0 mM, 2.0 mM, and 4.0 mM). (B) The band at ~55 kDa in A was verified as PPAR-α protein by western blotting. (C) Surface plasmon resonance analysis was used to detect the binding affinity of 4-PBA to PPAR-α, which revealed a concentration-dependent manner with a dissociation constant (KD) value of 12.25 μM. (D) The computer simulation model of the direct binding of 4-PBA to PPAR-α. The carboxyl groups form a hydrogen bond with MET220, ASN219, and GLU286 by hydrogen bonding as a donor. The phenyl ring extends into the functional region in α-helix.

in urea-cycle disorders as an ammonia scavenger. It has also been tested in clinical trials for the treatment of other diseases such as thalassemia and cystic fibrosis. In recent studies, 4-PBA has been reported to reduce hepatocellular lipid accumulation and hepatotoxicity during liver injury in vivo. To investigate the role of 4-PBA on liver, we studied its long-time effect under HCC-inducing environment. Unexpectedly, our data revealed that 4-PBA could promote HCC initiation in chemical-induced mice model via inflammation and ER stress independent
FIGURE 8  High PPAR-α expression in HCC was associated with poor prognosis. (A) Rates of disease recurrence and overall survival in 263 HCC patients with high PPAR-α expression (n = 131) and low expression (n = 132) were analyzed from a 6-year follow-up. High PPAR-α expression correlates with worse survival in HCC patients. (B) Univariate analysis of tumor recurrence and OS. (C) Multivariate analysis of tumor recurrence and OS. (D) Schematic depiction of the mechanisms underlying 4-PBA promoted CSCs initiation via upregulating PPAR-α and activating Wnt5b-Pzd5–β-catenin signaling pathway.
mechanism. We have also observed that 4-PBA cast a protective effect during DEN-induced liver injury demonstrated by alleviated inflammation and fibrosis. Nevertheless, 4-PBA increased liver tumorigenesis through initiation of LCSCs. Significant ductal reaction could be observed as soon as 2 weeks after 4-PBA administration. Meanwhile, the expression of CSC markers was notably increased in 4-PBA treated liver. Thus, the protective role of 4-PBA via reducing ER stress during liver fibrosis is not as comparable as its role on LCSCs initiation in HCC models.

In short-term driver gene-induced HCC model (referred to as hMetS45Y-β-catenin), hMet, and mutant β-catenin concomitant expression could lead to liver tumor development in mice. 4-PBA administration obviously accelerated liver tumor onset with earlier microscopic nodules (4W) and notable macroscopic tumors after 8 weeks. When S45Y-β-catenin was spared from this model, no visible liver tumor was observed as long as 22 weeks of plasmids injection according to the previous report. However, when 4-PBA was supplemented, massive liver tumor could be observed in every animal that investigated (eight of eight) after 14 weeks of plasmids injection. Although the onset of liver tumor was prolonged, and the intra-tumoral hemorrhage was not as severe as the original model, 4-PBA could indeed serve as a replacement of mutant β-catenin in promoting tumorigenesis, which could be considered as indirect evidence that it could activate β-catenin pathway. Therefore, we could conclude that 4-PBA also played pivotal role in tumorigenesis in this short-term HCC model.

In our study, we have observed significant increase of PPAR-α induced by 4-PBA both in mRNA level and protein level in vitro and in vivo. According to previous studies, 4-PBA is a non-classical peroxisome proliferator which could induce pleiotropic effects including transcriptional activation through histone deacetylase enzymes (HDAC) inhibition. This could be a possible explanation for the upregulation of PPAR-α in mRNA level. Besides, by DARTS assay, we also found that 4-PBA could directly bind to PPAR-α and prevent it from proteolysis, which provided a novel insight for PPAR-α regulation.

PPAR-α plays a key role in maintaining glucose and lipid homeostasis as well as in cell proliferation, differentiation, and inflammatory responses. The decrease of PPAR-α is widely implicated in preclinical models of non-alcoholic steatohepatitis (NASH), NAFLD, and alcoholic liver disease. Therefore, in many studies, PPAR-α is considered as a potential therapeutic target for these metabolism-related liver diseases. Activation of PPAR-α was considered to ameliorate ethanol-induced steatohepatitis and liver fibrosis in mice and exhibited a protective role in NAFLD or NASH models. However, the role of PPAR-α in hepatocarcinogenesis remained controversial. PPAR-α agonists caused increased incidence of liver tumors via PPAR-α-mediated manner as indicated by the resistance of Ppara-null mice to liver cancer under the stimulation of PPAR-α ligand. Whereas, PPAR-α humanized mice showed resistance to liver cancer tumorigenesis, probably due to different response to PPAR-α ligand (14,643) in different species. Although whether PPAR-α could directly cause HCC remained unclear, a bunch of studies have linked PPAR-α activation as part of the mechanism for HCC development. For example, Keratin 23 was considered a PPAR-α dependent, MYC-amplified oncogene that might remove rate-limiting constraints on hepatocyte proliferation and lead to liver cancer. Previous study has also reported a synergized effect of PPAR-α and glucocorticoid receptor to promote erythroid progenitor self-renewal. In this study, by using high throughput method to screen the pathways involved in 4-PBA-treated samples, we have identified PPAR-α as the regulator of downstream genes. PCR array revealed Fzd5 as one of the most altered genes in 4-PBA group (Figure S5A). CHIP-seq also suggested Wnt5b as the only candidate of Wnt signaling pathway-related genes with H3K4me3 modification under 4-PBA treatment. In vitro study validated that 4-PBA induced the release of Wnt5b in supernatant and its accumulation in cytoplasm in a dose-dependent manner. Further study revealed a positive correlation of PPAR-α expression and the activation of Wnt5b signaling pathway. However, if 4-PBA could regulate Wnt5b transcription via ways other than PPAR-α needs to be further investigated.

Although 4-PBA alone could not initiate the onset of liver tumor, it has a tumor-promoting role under HCC-inducing background. Since the role of Wnt signaling pathway is well understood in liver cancer, it is worth noticing that the connection between PPAR-α and Wnt signaling activation might limit the use of therapeutic modulators such as PPAR-α agonist in certain patients. Meanwhile, PPAR-α expression predicts poor prognosis in HCC patients, suggesting that more concern should be taken regarding the use of 4-PBA in clinics due to its role in promoting PPAR-α expression. Nevertheless, therapeutic modulators such as PPAR-α antagonist might serve as a potential adjuvant drug for patients under long-term 4-PBA treatment.

ACKNOWLEDGMENTS

We appreciate the support from Shanghai Key Laboratory of Hepato-biliary Tumor Biology and Ministry of Education Key Laboratory on Signaling Regulation and Targeting Therapy of Liver Cancer, Second Military Medical University, Shanghai, China. We also want to thank Liang Tang, Shan-Hua Tang, Lin-Na Guo, and Dan Cao for their technical assistances. This study is sponsored by National Natural Science Foundation of China (grant/award...
numbers: 81802878, 81722034, 81572896, 81773077, 82002522, 81830054, 91859205, and 81988101; Shanghai Sailing Program (grant/award number: 18YF1400200); Shanghai Pujiang Program (grant/award number: 18PJJD060); National Key R&D Program of China (grant/award number: 2018YFA0107500); National Major Scientific and Technological Special Project for “Significant New Drugs Development” and “Prevention and Control of Infectious Diseases” (grant numbers: 2018ZX09101002 and 2017ZX100203205004); Shanghai Education Committee Program: 201901070007E00065.

CONFLICT OF INTEREST
The authors have no conflict of interest to declare.

AUTHOR CONTRIBUTIONS
Conception and design: Le-Xing Yu, Wen Wen, and Hong-Yang Wang. Development of methodology: Xiao-Fei Chen, Shu-Zhen Chen, and Yan Ling. Acquisition of data (provided animals, provided facilities, etc.): Shu-Zhen Chen, Yan Ling, Yu-Ting Song, and Jiao-Jiao Tang. Collection of patients sample and clinical data: Can Chen. Patients’ Follow-up and data sorting: Ya-Ping Dong. Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): Shu-Zhen Chen, Qi-Qi Cao, Han Yu, and Yu-Shan Miao. Writing, review, and/or revision of the manuscript: Shu-Zhen Chen and Hong-Yang Wang. Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): Zhe-Cai Fan, Jun-Yan Tao, and Sadarshshan P.S. Monga. Study supervision: Wen Wen and Hong-Yang Wang.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Shu-Zhen Chen © https://orcid.org/0000-0002-8957-9404
Hong-Yang Wang © https://orcid.org/0000-0002-4709-3334

REFERENCES
1. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197–2233.
2. Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018.
3. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11(4):e1001624.
4. Chuang SC, La Vecchia C, Boffetta P. Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett. 2009;286(1):9–14.
5. Sagnelli E, Macera M, Russo A, Coppola N, Sagnelli C. Epidemiological and etiological variations in hepatocellular carcinoma. Infection. 2020;48(1):7–17.
6. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35–S50.
7. Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(2):477–491.e1.
8. Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16(7):411–428.
9. Gao B, Ahmad MF, Nagy LE, Tsukamoto H. Inflammatory pathways in alcoholic steatohepatitis. J Hepatol. 2019;70(2):249–259.
10. Szabo G, Mandrekar P, Dolganui A. Innate immune response and hepatic inflammation. Semin Liver Dis. 2007;27(4):339–350.
11. Lee B, Rhead W, Diaz GA, et al. Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. Mol Genet Metab. 2010;100(3):221–228.
12. Lichter-Konecki U, Diaz GA, Merritt JL, et al. Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate. Mol Genet Metab. 2011;103(4):323–329.
13. Iannitti T, Palmieri B. Clinical and experimental applications of sodium phenylbutyrate. Drugs R D. 2011;11(3):227–249.
14. Welch WJ, Brown CR. Influence of molecular and chemical chaperones on protein folding. Cell Stress Chaperones. 1996;1(2):109–115.
15. Ma W, Goldberg E, Goldberg J. ER retention is imposed by non-typical reversion of prostate cancer cells in vitro by nontoxic pharmacological concentration of phenylacetate. J Clin Invest. 1999;103(5):1243–1253.
23. Kusaczuł M, Bartoszewicz M, Cechowska-Pasko M. Phenylbutyric acid: simple structure - multiple effects. Curr Pharm Des. 2015;21(16):2147–2166.

24. Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;513(7516):59–64.

25. Yu LX, Yan H-X, Liu Q, et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology. 2010;52(4):1322–1333.

26. Zhang HL, Yu L-X, Yang W, et al. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. J Hepatol. 2012;57(4):803–812.

27. Xin L, Fan Wu, Tingting Du, Zuoming S, Qiang Z. 4-phenylbutyric acid attenuates endoplasmic reticulum stress-mediated apoptosis and protects the hepatocytes from intermittent hypoxia-induced injury. Sleep Breath. 2019;23(2):711–717.

28. Nissar AU, Sharma L, Mudasir MA, et al. Chemical chaperone 4-phenyl butyric acid (4-PBA) reduces hepatocellular lipid accumulation and lipotoxicity through induction of autophagy. J Lipid Res. 2017;58(9):1855–1868.

29. Lomenick B, Jung G, Wohlschlegel JA, Huang J. Target identification using drug affinity responsive target stability (DARTS). Curr Protoc Chem Biol. 2011;3(4):163–180.

30. Tao I, Xu E, Zhao Y, et al. Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant beta-catenin. Hepatology. 2016;64(5):1587–1605.

31. Maeda S, Kamata H, Luo J-L, Leffert H, Karin M. IKKbeta couples hepatic death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell. 2005;121(7):977–990.

32. Sakurai T, He G, Matsuzawa A, et al. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediates carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell. 2008;14(2):156–165.

33. He G, Dhar D, Nakagawa H, et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell. 2013;155(2):384–396.

34. Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene. 2006;25(27):3818–3822.

35. Clouston AD, Powell EE, Walsh MJ, Richardson MM, Demetris AJ, Jonsson JR. Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology. 2005;41(4):809–818.

36. Kato S, Hayakawa Y, Sakurai H, Saiki I, Yokoyama S. Mesenchymal-transitioned cancer cells instigate the invasion of epithelial cancer cells through secretion of WNT3 and WNT5B. Cancer Sci. 2014;105(3):281–289.

37. Gao J, Yuan S, Jin J, Shi J, Hou Y. PPARalpha regulates tumor progression, foe or friend?. Eur J Pharmacol. 2015;765:560–564.

38. Lomenick B, Hao R, Jonai N, et al. Target identification using drug affinity responsive target stability (DARTS). Proc Natl Acad Sci U S A. 2009;106(31):21984–21989.

39. Pai MY, Lomenick B, Hwang H, et al. Drug affinity responsive target stability (DARTS) for small-molecule target identification. Methods Mol Biol. 2015;1263:287–298.

40. Maestri NE, Brusilow SW, Clissold DB, Bassett SS. Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med. 1996;335(12):855–859.

41. Collins AF, Pearson HA, Giardina P, Mcdonagh KT, Brusilow SW, Dover GJ. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood. 1995;85(1):43–49.

42. Chen WY, Bailey EC, Mccune SL, Dong J-Y, Townes TM. Reaction of silenced, virally transduced genes by inhibitors of histone deacetylase. Proc Natl Acad Sci U S A. 1997;94(11):5798–5803.

43. Guo HL, Hassan HM, Ding P-P, et al. Pyrazinamide-induced hepatotoxicity is alleviated by 4-PBA via inhibition of the PERK-eIF2alpha-ATF4-CHOP pathway. Toxicology. 2017;378:65–75.

44. Bougarne N, Weyers B, Desmet SJ, et al. Molecular actions of PPARalpha in lipid metabolism and inflammation. Endocr Rev. 2018;39(5):760–802.

45. Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPA-Ralpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2015;62(3):720–733.

46. Francque S, Verrijken An, Caron S, et al. PPARalpha gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. J Hepatol. 2015;63(1):164–173.

47. Meng FG, Zhang X-N, Liu S-X, Wang Yi-R, Zeng T. Roles of peroxisome proliferator-activated receptor alpha in the pathogenesis of ethanol-induced liver disease. Chem Biol Interact. 2020;327:109176.

48. Nan YM, Wang RQ, Fu N. Peroxisome proliferator-activated receptor alpha, a potential therapeutic target for alcoholic liver disease. World J Gastroenterol. 2014;20(25):8055–8060.

49. Westerouen Van Meeteren MJ, Drenth JPH, Tjwa E. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Investig Drugs. 2020;29(2):117–123.

50. Honda Y, Kessoku T, Ogawa Y, et al. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. Sci Rep. 2017;7:42477.

51. Wan YJ, Morimoto M, Thurman RG, Bojes HK, French SW. Expression of the peroxisome proliferator-activated receptor gene is decreased in experimental alcoholic liver disease. Life Sci. 1995;56(5):307–317.

52. Kong L, Ren W, Li W, et al. Activation of peroxisome proliferator activated receptor alpha ameliorates ethanol induced steatohepatitis in mice. Liplids Health Dis. 2011;10:246.

53. Nan YM, Kong L-Bo, Ren W-G, et al. Activation of peroxisome proliferator activated receptor alpha ameliorates ethanol mediated liver fibrosis in mice. Liplids Health Dis. 2013;12:11.

54. Staels B, Rubenstrunk A, Noel B, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2013;58(6):1941–1952.

55. Ratziu V, Harrison SA, Franque S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150(5):1147-1159.e5.

56. Peters JM, Cattley RC, Gonzalez FJ. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis. 1997;18(11):2029–2033.
57. Cheung C, Akiyama TE, Ward JM, et al. Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha. *Cancer Res*. 2004;64(11):3849–3854.

58. Gonzalez FJ, Shah YM. PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. *Toxicology*. 2008;246(1):2–8.

59. Cui M, Xiao Z, Wang Y, et al. Long noncoding RNA HULC modulates abnormal lipid metabolism in hepatoma cells through an miR-9-mediated RXRA signaling pathway. *Cancer Res*. 2015;75(5):846–857.

60. Kim D, Brocker CN, Takahashi S, et al. Keratin 23 is a peroxisome proliferator-activated receptor alpha-dependent, MYC-amplified oncogene that promotes hepatocyte proliferation. *Hepatology*. 2019;70(1):154–167.

61. Senni N, Savall M, Cabrerizo Granados D, et al. beta-catenin-activated hepatocellular carcinomas are addicted to fatty acids. *Gut*. 2019;68(2):322–334.

62. Lee HY, Gao X, Barrasa MI, et al. PPAR-alpha and glucocorticoid receptor synergize to promote erythroid progenitor self-renewal. *Nature*. 2015;522(7557):474–477.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

---

**How to cite this article:** Chen S-Z, Ling Y, Yu L-X, et al. 4-phenylbutyric acid promotes hepatocellular carcinoma via initiating cancer stem cells through activation of PPAR-α. *Clin Transl Med*. 2021;11:e379. [https://doi.org/10.1002/ctm2.379](https://doi.org/10.1002/ctm2.379)